Seat­tle Ge­net­ic­s' Astel­las-part­nered ADC nails con­fir­ma­to­ry PhI­II in urothe­lial can­cer

Nine months af­ter Seat­tle Ge­net­ics nabbed an ac­cel­er­at­ed ap­proval for its Astel­las-part­nered an­ti­body-drug con­ju­gate Pad­cev, the part­ners said the ther­a­py has nailed a con­fir­ma­to­ry …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER